VIRVir Biotechnology Inc
$8.69
$0.65
(6.96%)
Closed $8.69
$0.05
(0.57%)
After Hours
EarningsAug 5
Mkt Cap$1.47B
Vol2.15M
Vir Biotechnology Announces Chief Financial Officer Transition
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Financial Officer, effective July 23. Jason OByrne is leaving the Company to pursue another opportunity and will remain with Vir...
Business Wire
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 5 to provide a corporate update and discuss its financial results for the second quarter ended June 30, 2026. The conference call may be accessed on the...
Business Wire
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. We are pleased to welcome Tim to Vir Biotechnologys Board of Directors at a pivotal moment for the company, said Marianne...
Business Wire
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now...
Yahoo! Finance: News
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
Key PointsSuperstring Capital acquired 730,548 shares of Vir Biotechnology last quarter; the estimated trade size was $5.82 million based on quarterly average prices...
Nasdaq News: Markets
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta...
Business Wire
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million...
Yahoo! Finance: News
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares...
Yahoo! Finance: News
Vir Biotechnology's Chairman of the Board Sold 22,000 Company Shares. Here's What That Means for Investors.
Key PointsVicki Sato sold 22,000 shares on May 1, 2026, generating a transaction value of ~$221,000 at around $10.05 per share...
Nasdaq News: Markets
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the first quarter ended March 31, 2026. Vir Bio delivered incredible momentum during the...
Business Wire
<
1
2
...
>
Advertisement|Remove ads.
HIMS5
6
SPY41
96HIMS5
2Advertisement|Remove ads.